Lung Malignancies in HIV Infection

 

 Buy Article Permissions and Reprints

Abstract

Pulmonary malignancies are a major source of morbidity and mortality in HIV-infected persons. Non–AIDS-defining lung cancers (mostly non-small cell lung cancers) are now a leading cause of cancer death among HIV-infected persons. HIV-associated factors appear to affect the risk of lung cancer and may adversely impact cancer treatment and outcomes. HIV infection also may modify the potential harms and benefits of lung cancer screening with computed tomography. AIDS-defining lung malignancies include pulmonary Kaposi sarcoma and pulmonary lymphoma, both of which are less prevalent with widespread adoption of antiretroviral therapy.

• References

• 1 Hakimian R, Fang H, Thomas L, Edelman MJ. Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy. J Thorac Oncol 2007; 2 (4) 268-272
  CrossrefPubMedGoogle Scholar
• 2 Engels EA, Pfeiffer RM, Goedert JJ , et al; HIV/AIDS Cancer Match Study. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20 (12) 1645-1654
  CrossrefPubMedGoogle Scholar
• 3 Levine AM. Non-Hodgkin's lymphomas and other malignancies in the acquired immune deficiency syndrome. Semin Oncol 1987; 14 (2) (Suppl. 03) 34-39
  PubMedGoogle Scholar
• 4 Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009; 52 (5) 611-622
  CrossrefPubMedGoogle Scholar
• 5 Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24 (9) 1383-1388
  CrossrefPubMedGoogle Scholar
• 6 Worm SW, Bower M, Reiss P , et al; D:A:D Study Group. Non-AIDS defining cancers in the D:A:D Study—time trends and predictors of survival: a cohort study. BMC Infect Dis 2013; 13: 471
  CrossrefPubMedGoogle Scholar
• 7 Phelps RM, Smith DK, Heilig CM , et al; HER Study Group. Cancer incidence in women with or at risk for HIV. Int J Cancer 2001; 94 (5) 753-757
  CrossrefPubMedGoogle Scholar
• 8 Kirk GD, Merlo C, O' Driscoll P , et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007; 45 (1) 103-110
  CrossrefPubMedGoogle Scholar
• 9 Chaturvedi AK, Pfeiffer RM, Chang L, Goedert JJ, Biggar RJ, Engels EA. Elevated risk of lung cancer among people with AIDS. AIDS 2007; 21 (2) 207-213
  CrossrefPubMedGoogle Scholar
• 10 Shiels MS, Cole SR, Mehta SH, Kirk GD. Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users. J Acquir Immune Defic Syndr 2010; 55 (4) 510-515
  CrossrefPubMedGoogle Scholar
• 11 Sigel K, Wisnivesky J, Gordon K , et al. HIV as an independent risk factor for incident lung cancer. AIDS 2012; 26 (8) 1017-1025
  CrossrefPubMedGoogle Scholar
• 12 Hessol NA, Seaberg EC, Preston-Martin S , et al; WIHS Collaborative Study Group. Cancer risk among participants in the women's interagency HIV study. J Acquir Immune Defic Syndr 2004; 36 (4) 978-985
  CrossrefPubMedGoogle Scholar
• 13 Crothers K, Goulet JL, Rodriguez-Barradas MC , et al. Impact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans. AIDS Educ Prev 2009; 21 (3, Suppl): 40-53
  CrossrefPubMedGoogle Scholar
• 14 Clifford GM, Lise M, Franceschi S , et al; Swiss HIV Cohort Study. Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. Br J Cancer 2012; 106 (3) 447-452
  CrossrefPubMedGoogle Scholar
• 15 Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TR ; INSIGHT SMART Study Group. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health 2010; 100 (10) 1896-1903
  CrossrefPubMedGoogle Scholar
• 16 Koshiol J, Rotunno M, Consonni D , et al. Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study. PLoS ONE 2009; 4 (10) e7380
  CrossrefPubMedGoogle Scholar
• 17 Agustí A, Edwards LD, Rennard SI , et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 2012; 7 (5) e37483
  CrossrefPubMedGoogle Scholar
• 18 Crothers K, Huang L, Goulet JL , et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med 2011; 183 (3) 388-395
  CrossrefPubMedGoogle Scholar
• 19 Diaz PT, King MA, Pacht ER , et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 2000; 132 (5) 369-372
  PubMedGoogle Scholar
• 20 Twigg HL, Soliman DM, Day RB , et al. Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virus infection. Am J Respir Crit Care Med 1999; 159 (5 Pt 1) 1439-1444
  CrossrefPubMedGoogle Scholar
• 21 Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009; 360 (23) 2445-2454
  CrossrefPubMedGoogle Scholar
• 22 Morris AM, Huang L, Bacchetti P , et al; The Pulmonary Complications of HIV Infection Study Group. Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons. Am J Respir Crit Care Med 2000; 162 (2 Pt 1): 612-616
  CrossrefPubMedGoogle Scholar
• 23 Morris A, Alexander T, Radhi S , et al. Airway obstruction is increased in pneumocystis-colonized human immunodeficiency virus-infected outpatients. J Clin Microbiol 2009; 47 (11) 3773-3776
  CrossrefPubMedGoogle Scholar
• 24 Christensen PJ, Preston AM, Ling T , et al. Pneumocystis murina infection and cigarette smoke exposure interact to cause increased organism burden, development of airspace enlargement, and pulmonary inflammation in mice. Infect Immun 2008; 76 (8) 3481-3490
  CrossrefPubMedGoogle Scholar
• 25 Attia EF, Akgün KM, Wongtrakool C , et al. Increased risk of radiographic emphysema in HIV is associated with elevated soluble CD14 and nadir CD4. Chest 2014; 146 (6) 1543-1553
  CrossrefPubMedGoogle Scholar
• 26 Crothers K, Sigel K, Wisnivesky J , et al. Inflammatory Biomarkers and CT-Detected Lung Nodules: Potential Implications for Lung Cancer Screening in HIV-Infected Patients. International Conference on Malignancies in AIDS and Other Immunodeficiencies. Bethesda, MD; 2013
  PubMedGoogle Scholar
• 27 Cho WC, Kwan CK, Yau S, So PP, Poon PC, Au JS. The role of inflammation in the pathogenesis of lung cancer. Expert Opin Ther Targets 2011; 15 (9) 1127-1137
  CrossrefPubMedGoogle Scholar
• 28 Wu AH, Fontham ET, Reynolds P , et al. Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1995; 141 (11) 1023-1032
  CrossrefPubMedGoogle Scholar
• 29 Liang HY, Li XL, Yu XS , et al. Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: a systematic review. Int J Cancer 2009; 125 (12) 2936-2944
  CrossrefPubMedGoogle Scholar
• 30 Mayne ST, Buenconsejo J, Janerich DT. Previous lung disease and risk of lung cancer among men and women nonsmokers. Am J Epidemiol 1999; 149 (1) 13-20
  CrossrefPubMedGoogle Scholar
• 31 Littman AJ, Thornquist MD, White E, Jackson LA, Goodman GE, Vaughan TL. Prior lung disease and risk of lung cancer in a large prospective study. Cancer Causes Control 2004; 15 (8) 819-827
  CrossrefPubMedGoogle Scholar
• 32 Ramanakumar AV, Parent ME, Menzies D, Siemiatycki J. Risk of lung cancer following nonmalignant respiratory conditions: evidence from two case-control studies in Montreal, Canada. Lung Cancer 2006; 53 (1) 5-12
  CrossrefPubMedGoogle Scholar
• 33 Shebl FM, Engels EA, Goedert JJ, Chaturvedi AK. Pulmonary infections and risk of lung cancer among persons with AIDS. J Acquir Immune Defic Syndr 2010; 55 (3) 375-379
  CrossrefPubMedGoogle Scholar
• 34 Bordon J, Aliberti S, Fernandez-Botran R , et al. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. Int J Infect Dis 2013; 17 (2) e76-e83
  CrossrefPubMedGoogle Scholar
• 35 Rubbo PA, Tuaillon E, Bolloré K , et al. The potential impact of CD4+ T cell activation and enhanced Th1/Th2 cytokine ratio on HIV-1 secretion in the lungs of individuals with advanced AIDS and active pulmonary infection. Clin Immunol 2011; 139 (2) 142-154
  CrossrefPubMedGoogle Scholar
• 36 Dubrow R, Silverberg MJ, Park LS, Crothers K, Justice AC. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol 2012; 24 (5) 506-516
  CrossrefPubMedGoogle Scholar
• 37 Yanik EL, Napravnik S, Cole SR , et al. Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence. AIDS 2014; 28 (7) 979-987
  CrossrefPubMedGoogle Scholar
• 38 Silverberg MJ, Chao C, Leyden WA , et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev 2011; 20 (12) 2551-2559
  CrossrefPubMedGoogle Scholar
• 39 Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D ; Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10 (12) 1152-1159
  CrossrefPubMedGoogle Scholar
• 40 Reekie J, Kosa C, Engsig F , et al; EuroSIDA Study Group. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer 2010; 116 (22) 5306-5315
  CrossrefPubMedGoogle Scholar
• 41 Kesselring A, Gras L, Smit C , et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2011; 52 (12) 1458-1465
  CrossrefPubMedGoogle Scholar
• 42 Hleyhel M, Hleyhel M, Bouvier AM , et al; Cancer Risk Group of the French Hospital Database on HIV (FHDH-ANRS CO4). Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort. AIDS 2014; 28 (14) 2109-2118
  CrossrefPubMedGoogle Scholar
• 43 Sigel K, Crothers K, Gordon K , et al. CD4 Measures as Predictors of Lung Cancer Risk and Prognosis in HIV Infection. Conference on Retroviruses and Opportunistic Infections. Seattle, WA; 2015
  PubMedGoogle Scholar
• 44 Poirier MC, Olivero OA, Walker DM, Walker VE. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol 2004; 199 (2) 151-161
  CrossrefPubMedGoogle Scholar
• 45 Vivanti A, Soheili TS, Cuccuini W , et al. Comparing genotoxic signatures in cord blood cells from neonates exposed in utero to zidovudine or tenofovir. AIDS 2015; 29 (11) 1319-1324
  CrossrefPubMedGoogle Scholar
• 46 André-Schmutz I, Dal-Cortivo L, Six E , et al. Genotoxic signature in cord blood cells of newborns exposed in utero to a Zidovudine-based antiretroviral combination. J Infect Dis 2013; 208 (2) 235-243
  CrossrefPubMedGoogle Scholar
• 47 Bruyand M, Le Marec F, Lavole A , et al. Protease inhibitors exposure is not related to lung cancer risk in HIV smoker patients: a nested case-control study. AIDS 2015; 29 (9) 1105-1109
  CrossrefPubMedGoogle Scholar
• 48 Beltrán LM, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, García-Puig J, Moreno JA. Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus. Vasc Health Risk Manag 2015; 11: 35-48
  PubMedGoogle Scholar
• 49 Lu W, Mehraj V, Vyboh K, Cao W, Li T, Routy JP. CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients. J Int AIDS Soc 2015; 18: 20052
  PubMedGoogle Scholar
• 50 Borges AH, Silverberg MJ, Wentworth D , et al; INSIGHT SMART; ESPRIT; SILCAAT Study Groups. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS 2013; 27 (9) 1433-1441
  CrossrefPubMedGoogle Scholar
• 51 Altavilla G, Caputo A, Lanfredi M, Piola C, Barbanti-Brodano G, Corallini A. Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene. Am J Pathol 2000; 157 (4) 1081-1089
  CrossrefPubMedGoogle Scholar
• 52 Giagulli C, Marsico S, Magiera AK , et al. Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS ONE 2011; 6 (3) e17831
  CrossrefPubMedGoogle Scholar
• 53 Kawabata S, Heredia A, Gills J, Redfield RR, Dennis PA, Bryant J. Impact of HIV on lung tumorigenesis in an animal model. AIDS 2015; 29 (5) 633-635
  PubMedGoogle Scholar
• 54 Hasegawa Y, Ando M, Kubo A , et al. Human papilloma virus in non-small cell lung cancer in never smokers: a systematic review of the literature. Lung Cancer 2014; 83 (1) 8-13
  CrossrefPubMedGoogle Scholar
• 55 De Paoli P, Carbone A. Carcinogenic viruses and solid cancers without sufficient evidence of causal association. Int J Cancer 2013; 133 (7) 1517-1529
  CrossrefPubMedGoogle Scholar
• 56 Brock MV, Hooker CM, Engels EA , et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 2006; 43 (1) 47-55
  CrossrefPubMedGoogle Scholar
• 57 Vyzula R, Remick SC. Lung cancer in patients with HIV-infection. Lung Cancer 1996; 15 (3) 325-339
  CrossrefPubMedGoogle Scholar
• 58 D'Jaen GA, Pantanowitz L, Bower M , et al. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer 2010; 11 (6) 396-404
  CrossrefPubMedGoogle Scholar
• 59 Sigel K, Crothers K, Dubrow R , et al. Prognosis in HIV-infected patients with non-small cell lung cancer. Br J Cancer 2013; 109 (7) 1974-1980
  CrossrefPubMedGoogle Scholar
• 60 Wistuba II, Behrens C, Milchgrub S , et al. Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA 1998; 279 (19) 1554-1559
  CrossrefPubMedGoogle Scholar
• 61 Okuma Y, Tanuma J, Kamiryo H , et al. A multi-institutional study of clinicopathological features and molecular epidemiology of epidermal growth factor receptor mutations in lung cancer patients living with human immunodeficiency virus infection. J Cancer Res Clin Oncol 2015; 141 (9) 1669-1678
  CrossrefPubMedGoogle Scholar
• 62 Sigel K, Sigel C, Wisnivesky J , et al. Rates of Cancer Mutations in HIV Infected Non-Small Cell Lung Cancer Patients. 14th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies. Bethesda, MD; 2013
  PubMedGoogle Scholar
• 63 Howlader NNA, Krapcho M, Neyman N, , et al. In: Edwards BK. , ed. SEER Cancer Statistics Review 1975–2008. Bethesda, MD: National Cancer Institute; 2011
  Google Scholar
• 64 Tirelli U, Spina M, Sandri S , et al; The Italian Cooperative Group on AIDS and Tumors. Lung carcinoma in 36 patients with human immunodeficiency virus infection. Cancer 2000; 88 (3) 563-569
  CrossrefPubMedGoogle Scholar
• 65 Biggar RJ, Engels EA, Ly S , et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005; 39 (3) 293-299
  CrossrefPubMedGoogle Scholar
• 66 Suneja G, Shiels MS, Melville SK, Williams MA, Rengan R, Engels EA. Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS 2013; 27 (3) 459-468
  CrossrefPubMedGoogle Scholar
• 67 Poluri A, Shah KG, Carew JF , et al. Hodgkin's disease of the head and neck in human immunodeficiency virus-infected patients. Am J Otolaryngol 2002; 23 (1) 12-16
  CrossrefPubMedGoogle Scholar
• 68 Bourcier V, Winnock M, Ait Ahmed M , et al; ANRS CO13 Hepavih study group; ANRS CO12 Cirvir study group. Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). Clin Res Hepatol Gastroenterol 2012; 36 (3) 214-221
  CrossrefPubMedGoogle Scholar
• 69 Rodrigues LK, Klencke BJ, Vin-Christian K , et al. Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol 2002; 138 (6) 765-770
  CrossrefPubMedGoogle Scholar
• 70 Hooker CM, Meguid RA, Hulbert A , et al. Human immunodeficiency virus infection as a prognostic factor in surgical patients with non-small cell lung cancer. Ann Thorac Surg 2012; 93 (2) 405-412
  CrossrefPubMedGoogle Scholar
• 71 Makinson A, Tenon JC, Eymard-Duvernay S , et al. Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study. J Thorac Oncol 2011; 6 (6) 1022-1029
  CrossrefPubMedGoogle Scholar
• 72 Ferketich AK, Diaz P, Browning KK , et al. Safety of varenicline among smokers enrolled in the lung HIV study. Nicotine Tob Res 2013; 15 (1) 247-254
  CrossrefPubMedGoogle Scholar
• 73 Lloyd-Richardson EE, Stanton CA, Papandonatos GD , et al. Motivation and patch treatment for HIV+ smokers: a randomized controlled trial. Addiction 2009; 104 (11) 1891-1900
  CrossrefPubMedGoogle Scholar
• 74 Shuter J, Morales DA, Considine-Dunn SE, An LC, Stanton CA. Feasibility and preliminary efficacy of a web-based smoking cessation intervention for HIV-infected smokers: a randomized controlled trial. J Acquir Immune Defic Syndr 2014; 67 (1) 59-66
  PubMedGoogle Scholar
• 75 Jaklitsch MT, Jacobson FL, Austin JH , et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg 2012; 144 (1) 33-38
  CrossrefPubMedGoogle Scholar
• 76 National Comprehensive Cancer Network Lung Cancer Screening Guidelines. Thorac Surg Clin 2015; 25 (2) 185-197
  CrossrefPubMedGoogle Scholar
• 77 Bach PB, Mirkin JN, Oliver TK , et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012; 307 (22) 2418-2429
  CrossrefPubMedGoogle Scholar
• 78 Nakagawa F, May M, Phillips A. Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis 2013; 26 (1) 17-25
  CrossrefPubMedGoogle Scholar
• 79 Aberle DR, Adams AM, Berg CD , et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365 (5) 395-409
  CrossrefPubMedGoogle Scholar
• 80 Crum-Cianflone N, Stepenosky J, Medina S, Wessman D, Krause D, Boswell G. Clinically significant incidental findings among human immunodeficiency virus-infected men during computed tomography for determination of coronary artery calcium. Am J Cardiol 2011; 107 (4) 633-637
  CrossrefPubMedGoogle Scholar
• 81 Crothers K, Thompson BW, Burkhardt K , et al; Lung HIV Study. HIV-associated lung infections and complications in the era of combination antiretroviral therapy. Proc Am Thorac Soc 2011; 8 (3) 275-281
  CrossrefPubMedGoogle Scholar
• 82 Cohen JV, Stern J, Henry D. Correlating age-at-diagnosis of lung cancer in the HIV/AIDS population (Abstract #437). 49th Infectious Diseases Society of America Conference. Boston; 2011
  PubMedGoogle Scholar
• 83 Diaz PT, Clanton TL, Pacht ER. Emphysema-like pulmonary disease associated with human immunodeficiency virus infection. Ann Intern Med 1992; 116 (2) 124-128
  CrossrefPubMedGoogle Scholar
• 84 Kuhlman JE, Knowles MC, Fishman EK, Siegelman SS. Premature bullous pulmonary damage in AIDS: CT diagnosis. Radiology 1989; 173 (1) 23-26
  CrossrefPubMedGoogle Scholar
• 85 Morris A, George MP, Crothers K , et al; Lung HIV Study. HIV and chronic obstructive pulmonary disease: is it worse and why?. Proc Am Thorac Soc 2011; 8 (3) 320-325
  CrossrefPubMedGoogle Scholar
• 86 Petrache I, Diab K, Knox KS , et al. HIV associated pulmonary emphysema: a review of the literature and inquiry into its mechanism. Thorax 2008; 63 (5) 463-469
  CrossrefPubMedGoogle Scholar
• 87 Wiener RS, Schwartz LM, Woloshin S, Welch HG. Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med 2011; 155 (3) 137-144
  CrossrefPubMedGoogle Scholar
• 88 Wu CC, Maher MM, Shepard JA. Complications of CT-guided percutaneous needle biopsy of the chest: prevention and management. AJR Am J Roentgenol 2011; 196 (6) W678-82
  CrossrefPubMedGoogle Scholar
• 89 Black C, Bagust A, Boland A , et al. The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. Health Technol Assess 2006; 10 (3) iii-iv , ix–x, 1–90
  PubMedGoogle Scholar
• 90 Goulart BH, Bensink ME, Mummy DG, Ramsey SD. Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness. J Natl Compr Canc Netw 2012; 10 (2) 267-275
  PubMedGoogle Scholar
• 91 Poghosyan H, Kennedy Sheldon L, Cooley ME. The impact of computed tomography screening for lung cancer on smoking behaviors: a teachable moment?. Cancer Nurs 2012; 35 (6) 446-475
  PubMedGoogle Scholar
• 92 Sigel K, Wisnivesky J, Shahrir S , et al. Findings in asymptomatic HIV-infected patients undergoing chest computed tomography testing: implications for lung cancer screening. AIDS 2014; 28 (7) 1007-1014
  CrossrefPubMedGoogle Scholar
• 93 Clausen E, Wittman C, Gingo M , et al. Chest computed tomography findings in HIV-infected individuals in the era of antiretroviral therapy. PLoS ONE 2014; 9 (11) e112237
  CrossrefPubMedGoogle Scholar
• 94 Hulbert A, Hooker CM, Keruly JC , et al. Prospective CT screening for lung cancer in a high-risk population: HIV-positive smokers. J Thorac Oncol 2014; 9 (6) 752-759
  CrossrefPubMedGoogle Scholar
• 95 Makinson A, Eymard-Duvernay S, Raffi F , et al. High Frequency of Early Lung Cancer Diagnosis with Chest CT in HIV Infected Smokers. Conference on Retroviruses and Opportunistic Infections. Seattle, WA; 2015
  PubMedGoogle Scholar
• 96 International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92 (22) 1823-1830
  CrossrefPubMedGoogle Scholar
• 97 Gramolelli S, Schulz TF. The role of Kaposi sarcoma-associated herpesvirus in the pathogenesis of Kaposi sarcoma. J Pathol 2015; 235 (2) 368-380
  CrossrefPubMedGoogle Scholar
• 98 Shiels MS, Pfeiffer RM, Gail MH , et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011; 103 (9) 753-762
  CrossrefPubMedGoogle Scholar
• 99 Palmieri C, Dhillon T, Thirlwell C , et al. Pulmonary Kaposi sarcoma in the era of highly active antiretroviral therapy. HIV Med 2006; 7 (5) 291-293
  CrossrefPubMedGoogle Scholar
• 100 Pinzone MR, Berretta M, Cacopardo B, Nunnari G. Epstein-barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection. Semin Oncol 2015; 42 (2) 258-271
  CrossrefPubMedGoogle Scholar
• 101 Leidner RS, Aboulafia DM. Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 2005; 19 (10) 635-644
  CrossrefPubMedGoogle Scholar
• 102 Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med 2007; 357 (13) 1352-1353
  CrossrefPubMedGoogle Scholar
• 103 Ensoli B, Stürzl M. Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. Cytokine Growth Factor Rev 1998; 9 (1) 63-83
  CrossrefPubMedGoogle Scholar
• 104 Aka PV, Kemp TJ, Rabkin CS , et al. A multiplex panel of plasma markers of immunity and inflammation in classical Kaposi sarcoma. J Infect Dis 2015; 211 (2) 226-229
  CrossrefPubMedGoogle Scholar
• 105 Foster CB, Lehrnbecher T, Samuels S , et al. An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood 2000; 96 (7) 2562-2567
  PubMedGoogle Scholar
• 106 Masiá M, Robledano C, Ortiz de la Tabla V , et al. Coinfection with human herpesvirus 8 is associated with persistent inflammation and immune activation in virologically suppressed HIV-infected patients. PLoS ONE 2014; 9 (8) e105442
  CrossrefPubMedGoogle Scholar
• 107 Khalil AM, Carette MF, Cadranel JL, Mayaud CM, Bigot JM. Intrathoracic Kaposi's sarcoma. CT findings. Chest 1995; 108 (6) 1622-1626
  CrossrefPubMedGoogle Scholar
• 108 Hoskote SS, Patel VP. Pulmonary Kaposi sarcoma in AIDS. Mayo Clin Proc 2012; 87 (10) e77
  CrossrefPubMedGoogle Scholar
• 109 Hamm PG, Judson MA, Aranda CP. Diagnosis of pulmonary Kaposi's sarcoma with fiberoptic bronchoscopy and endobronchial biopsy. A report of five cases. Cancer 1987; 59 (4) 807-810
  CrossrefPubMedGoogle Scholar
• 110 Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 2004; 22 (3) 399-402
  CrossrefPubMedGoogle Scholar
• 111 Gbabe OF, Okwundu CI, Dedicoat M, Freeman EE. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults. Cochrane Database Syst Rev 2014; 8: CD003256
  PubMedGoogle Scholar
• 112 Ray P, Antoine M, Mary-Krause M , et al. AIDS-related primary pulmonary lymphoma. Am J Respir Crit Care Med 1998; 158 (4) 1221-1229
  CrossrefPubMedGoogle Scholar
• 113 Bazot M, Cadranel J, Benayoun S, Tassart M, Bigot JM, Carette MF. Primary pulmonary AIDS-related lymphoma: radiographic and CT findings. Chest 1999; 116 (5) 1282-1286
  CrossrefPubMedGoogle Scholar
• 114 Cadranel J, Wislez M, Antoine M. Primary pulmonary lymphoma. Eur Respir J 2002; 20 (3) 750-762
  CrossrefPubMedGoogle Scholar
• 115 Starzl TE, Nalesnik MA, Porter KA , et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1 (8377) 583-587
  PubMedGoogle Scholar
• 116 Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA ; HIV/AIDS Cancer Match Study. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99 (12) 962-972
  CrossrefPubMedGoogle Scholar
• 117 Cadranel J, Naccache J, Wislez M, Mayaud C. Pulmonary malignancies in the immunocompromised patient. Respiration 1999; 66 (4) 289-309
  CrossrefPubMedGoogle Scholar
• 118 Marks MA, Rabkin CS, Engels EA , et al. Markers of microbial translocation and risk of AIDS-related lymphoma. AIDS 2013; 27 (3) 469-474
  CrossrefPubMedGoogle Scholar
• 119 Dean M, Jacobson LP, McFarlane G , et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res 1999; 59 (15) 3561-3564
  PubMedGoogle Scholar
• 120 Rabkin CS, Yang Q, Goedert JJ, Nguyen G, Mitsuya H, Sei S. Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1-infected individuals. Blood 1999; 93 (6) 1838-1842
  PubMedGoogle Scholar
• 121 Spina M, Carbone A, Vaccher E , et al. Outcome in patients with non-Hodgkin lymphoma and with or without human immunodeficiency virus infection. Clin Infect Dis 2004; 38 (1) 142-144
  CrossrefPubMedGoogle Scholar
• 122 Navarro JT, Lloveras N, Ribera JM, Oriol A, Mate JL, Feliu E. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica 2005; 90 (5) 704-706
  PubMedGoogle Scholar
• 123 Diamond C, Taylor TH, Im T, Anton-Culver H. Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma 2006; 47 (9) 1822-1829
  CrossrefPubMedGoogle Scholar
• 124 Ribera JM, Oriol A, Morgades M , et al; PETHEMA, GELTAMO, GELCAB and GESIDA Groups. Safety and efficacy of cyclophosphamide, Adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol 2008; 140 (4) 411-419
  CrossrefPubMedGoogle Scholar
• 125 Barta SK, Xue X, Wang D , et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood 2013; 122 (19) 3251-3262
  CrossrefPubMedGoogle Scholar
• 126 Kaplan LD, Lee JY, Ambinder RF , et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005; 106 (5) 1538-1543
  CrossrefPubMedGoogle Scholar
• 127 Spina M, Jaeger U, Sparano JA , et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005; 105 (5) 1891-1897
  CrossrefPubMedGoogle Scholar
• 128 Cooksley N, Judge DJ, Brown J. Primary pulmonary Hodgkin's lymphoma and a review of the literature since 2006. BMJ Case Rep . 2014 Apr 7.
  PubMedGoogle Scholar
• 129 Barta SK, Samuel MS, Xue X , et al. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Ann Oncol 2015; 26 (5) 958-966
  CrossrefPubMedGoogle Scholar
• 130 Massera F, Rocco G, Rossi G , et al. Pulmonary resection for lung cancer in HIV-positive patients with low (<200 lymphocytes/mm(3)) CD4(+) count. Lung Cancer 2000; 29 (2) 147-149
  PubMedGoogle Scholar
• 131 Bearz A, Vaccher E, Martellotta F , et al; Italian Cooperative Group on AIDS and Tumors. Lung cancer in HIV positive patients: the GICAT experience. Eur Rev Med Pharmacol Sci 2014; 18 (4) 500-508
  PubMedGoogle Scholar
• 132 Powles T, Thirwell C, Newsom-Davis T , et al. Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART?. Br J Cancer 2003; 89 (3) 457-459
  CrossrefPubMedGoogle Scholar
• 133 Lavolé A, Chouaïd C, Baudrin L , et al. Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. Lung Cancer 2009; 65 (3) 345-350
  CrossrefPubMedGoogle Scholar